Market closedNon-fractional
Kymera Therapeutic/KYMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Ticker
KYMR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Watertown, United States
Employees
186
Website
www.kymeratx.com
KYMR Metrics
BasicAdvanced
$2.7B
Market cap
-
P/E ratio
-$2.51
EPS
2.27
Beta
-
Dividend rate
Price and volume
Market cap
$2.7B
Beta
2.27
Financial strength
Current ratio
9.571
Quick ratio
9.309
Long term debt to equity
10.845
Total debt to equity
12.236
Interest coverage (TTM)
-896.94%
Management effectiveness
Return on assets (TTM)
-14.60%
Return on equity (TTM)
-26.35%
Valuation
Price to revenue (TTM)
34.112
Price to book
3.82
Price to tangible book (TTM)
3.82
Price to free cash flow (TTM)
-19.872
Growth
Revenue change (TTM)
70.16%
Earnings per share change (TTM)
-12.20%
3-year revenue growth (CAGR)
17.22%
3-year earnings per share growth (CAGR)
13.84%
What the Analysts think about KYMR
Analyst Ratings
Majority rating from 17 analysts.
KYMR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-78.66%
Net income
-$49M
239.16%
Profit margin
-475.49%
1,489.74%
KYMR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.90
-$0.25
-$0.69
-
Expected
-$0.64
-$0.64
-$0.41
-$0.73
-$0.68
Surprise
5.24%
40.33%
-38.27%
-5.08%
-
KYMR News
AllArticlesVideos
Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
Seeking Alpha·2 weeks ago
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
Investopedia·2 weeks ago
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $2.7B as of July 27, 2024.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of July 27, 2024.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Kymera Therapeutic stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.